What the business is, and whether it's a good one at a fair price.
Operates as a biopharmaceutical company with three reporting segments. Biosimilars is the largest at 60.2% of segment revenue (₹10,431.2 crore in FY26) and makes biologic copies of approved drugs — insulins, ustekinumab (sold as Yesintek), adalimumab, aflibercept (Yesafili) and denosumab — selling to global markets, with 12 biosimilar products commercialized worldwide. The CRDMO segment (21.6%, ₹3,738.7 crore) is the Syngene contract research, development and manufacturing business that serves external pharma clients. Generics (18.3%, ₹3,168.1 crore) sells small-molecule generic finished dosages and APIs, including a legacy lenalidomide contribution. Cost structure is dominated by materials at 31.2% of revenue and employees at 20.7%, with depreciation at 11.6% and capex at 10.6% of revenue, reflecting the asset-heavy biologics manufacturing base.
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from BIOCON LIMITED.'s filed financials and exchange disclosures
BIOCON LIMITED. is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol BIOCON.
Yes. Over the trailing twelve months BIOCON LIMITED. reported a net profit of ₹416 Cr on revenue of ₹17,321 Cr.
Yes. The dividend yield is 0.14% at the current price. It paid out 25% of its profit as dividend in FY26.
No. Debt stands at 0.40× equity, and it carries net debt of ₹12,408 Cr. That is lower than 24% of its 171 Pharmaceuticals peers.
On trailing P/E, BIOCON LIMITED. ranks 163 of 169 in Pharmaceuticals — cheaper than 4% of them, against an industry median of 28.9×. This is a position, not a valuation judgement.
On a typical session BIOCON LIMITED. moves 0.87% — that is the median absolute close-to-close move across its last 269 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by BIOCON LIMITED. appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
